Main Study: Percentage of Participants Who Had Progression of Coronavirus Disease 2019 (COVID-19) Through Day 29 by Hospitalization >24 Hours or Death Due to Any Cause (Weekly and Daily Imputation);Safety Sub-study: Number of Participants With Any Disease Related Events Through Day 8;Safety Sub-study: Number of Participants With Infusion-related Reaction Including Hypersensitivity Through Day 8;Safety Sub-study: Number of Participants With Non-Serious Adverse Events (Non-SAE) and Serious Adverse Events (SAEs) Through Day 8

Main Study: Percentage of Participants Who Had Progression of Coronavirus Disease 2019 (COVID-19) Through Day 29 by Hospitalization >24 Hours or Death Due to Any Cause (Weekly and Daily Imputation);Safety Sub-study: Number of Participants With Any Disease Related Events Through Day 8;Safety Sub-study: Number of Participants With Infusion-related Reaction Including Hypersensitivity Through Day 8;Safety Sub-study: Number of Participants With Non-Serious Adverse Events (Non-SAE) and Serious Adverse Events (SAEs) Through Day 8

Number of Participants Who Had Progression of COVID-19 Through Day 29 by Hospitalization >24 Hours or Death Due to Any Cause

Number of Participants Who Had Progression of COVID-19 Through Day 29 by Hospitalization >24 Hours or Death Due to Any Cause

Occurrence of adverse events (AEs) in Safety Sub-study;Occurrence of adverse events of special interest (AESIs) in Safety Sub-study;Occurrence of disease related events (DREs) in Safety Sub-study;Occurrence of serious adverse events (SAEs) in Safety Sub-study;Progression of COVID-19 in Main Study

Occurrence of adverse events (AEs) in Safety Sub-study;Occurrence of adverse events of special interest (AESIs) in Safety Sub-study;Occurrence of disease related events (DREs) in Safety Sub-study;Occurrence of serious adverse events (SAEs) in Safety Sub-study;Progression of COVID-19 in Main Study

Proportion of participants who have progression of COVID-19

Proportion of participants who have progression of COVID-19